Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer

Loading...
Thumbnail Image

Date

Authors

Vasista, A
Martin, Andrew
Pavlakis, N.
Sjoquist, Katrin
Snow, Stephanie
Jonker, Derek J
Chua, YuJo
Epstein, Richard
Bonaventura, Antonino
Khasraw, M

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley

Abstract

Background: We have proposed that best, worst and typical scenarios for survival, based on simple multiples of an individual's expected survival time (EST) estimated by their oncologist, are a useful way of formulating and explaining prognosis in advanced cancer. We aimed to determine the accuracy and prognostic significance of such estimates in a multicentre, randomised trial. Methods: Sixty‐six oncologists estimated the EST at baseline for each of 152 participants in the INTEGRATE trial. We expected oncologists’ estimates of EST to be well calibrated (∼50% of patients living longer than their EST) and imprecise (<33% living within 0.67–1.33 times their EST), but to provide accurate scenarios for survival time (∼10% dying within a quarter of their EST, ∼10% living longer than three times their EST and ∼50% living for half to double their EST). We hypothesised that oncologists’ estimates of EST would be independently predictive of overall survival in a Cox model including conventional prognostic factors. Results: Oncologists’ estimates of EST were well calibrated (45% shorter than observed), imprecise (29% lived within 0.67–1.33 times observed), and moderately discriminative (Harrell C‐statistic 0.62, P = 0.001). Scenarios derived from oncologists’ estimates were remarkably accurate: 9% of patients died within a quarter of their EST, 12% lived longer than three times their EST and 57% lived within half to double their EST. Oncologists estimates of EST were independently significant predictors of overall survival (HR = 0.89; 95% CI, 0.83–0.95; P = 0.001) in a Cox model including conventional prognostic factors. Conclusions: Oncologists’ estimates of survival time were well calibrated, moderately discriminative and independently significant predictors of overall survival. Best, worst and typical scenarios for survival based on simple multiples of the EST were remarkably accurate and would provide a useful method for estimating and explaining prognosis in this setting.

Description

Keywords

Citation

Source

Asia-Pacific Journal of Clinical Oncology

Book Title

Entity type

Access Statement

License Rights

Restricted until

2099-12-31